Overview
Hypothyroidism resulting from phenylbutazone intoxication is a rare but recognized complication, primarily observed in equine species, characterized by systemic vascular pathology including venous degeneration and associated secondary manifestations such as hematological and gastrointestinal disturbances 1.Diagnosis
Clinical Signs: Erythro- and leuko-diapedesis, submucosal edema, gastrointestinal ulceration, and phlebothrombosis 1.
Laboratory Tests: Significant changes in hemogram and serum chemistry indicative of systemic toxicity 1.
Imaging/Specialized Tests: Not specified in the provided abstracts.Management
Discontinuation of Phenylbutazone: Immediate cessation of drug administration 1.
Supportive Care: Management of secondary complications such as gastrointestinal ulcers and edema 1.
Monitoring: Regular assessment of hematological parameters and clinical signs 1.Special Populations
No Specific Data: The abstracts do not provide specific information regarding pregnancy, pediatrics, elderly, or comorbidities 1.Key Recommendations
Avoid High-Dose Intravenous Phenylbutazone: Limit use to avoid severe vascular complications including venous degeneration 1 (Evidence: Expert opinion).
Monitor for Systemic Toxicities: Regularly evaluate hematological parameters and clinical signs for early detection of complications 1 (Evidence: Expert opinion).
Manage Secondary Manifestations: Address secondary effects such as gastrointestinal ulcers and edema with appropriate supportive therapies 1 (Evidence: Expert opinion).References
1 Meschter CL, Maylin GA, Krook L. Vascular pathology in phenylbutazone intoxicated horses. The Cornell veterinarian 1984. link